The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

ABSTRACT: Treatment for Hodgkin lymphoma (HL) has evolved considerably from the time it was originally described in the 19th century with many patients now being cured with frontline therapy. Despite these advances, upwards of 10% of patients experience progressive disease after initial therapy with an even higher percentage relapsing. Until recently there had been limited therapeutic options for relapsed and/or refractory HL outside of highly intensive chemotherapy with stem cell rescue. Improved understanding of the pathophysiology of HL, coupled with the emergence of more targeted therapeutics, has reshaped how we view the treatment of relapsed/refractory HL and its prognosis. With this, there has been an increased focus on immunotherapies that can reprogram the immune system to better overcome t

SUBMITTER: Meier JA 

PROVIDER: S-EPMC8877886 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature